DiaMedica Therapeutics Inc. Stock Toronto S.E.
Equities
DMA
CA25253X2077
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 123M 89.21M |
---|---|---|---|---|---|
Net income 2024 * | -35M -25.45M | Net income 2025 * | -47M -34.17M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-3.42
x | P/E ratio 2025 * |
-2.73
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.96% |
Latest transcript on DiaMedica Therapeutics Inc.
Managers | Title | Age | Since |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 05-03-31 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 18-03-31 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 23-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 23-05-29 |
Tanya Lewis
BRD | Director/Board Member | 53 | 23-02-28 |
James Parsons
BRD | Director/Board Member | 58 | 10-10-19 |
1st Jan change | Capi. | |
---|---|---|
+17.73% | 124B | |
+16.88% | 111B | |
-9.04% | 23.17B | |
+5.18% | 22.94B | |
-38.15% | 17.42B | |
-7.75% | 17.42B | |
-14.59% | 16.9B | |
+3.42% | 13.71B | |
+29.63% | 11.82B |